Arietis Corp

Category
Spinouts
About This Project

Arietis bridges an important gap in antimicrobial drug discovery and technology development by identifying and developing compounds to kill “persister” cells.

Value Proposition

Current antibiotics are often unable to completely eradicate chronic diseases and biofilms, owing to the antiobiotic tolerance of “persister” cells, a phenotypic variants of regular bacteria. Persisters are largely responsible for the difficulty in treating chronic diseases such as tuberculosis, and various infections associated with biofilms – endocarditis, osteomyelitis, infections of catheters and in-dwelling devices, and deep-seated infections of soft tissues.